Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment

Oncology (Switzerland)

Volumn 84, Issue 1, 2012, Pages 43-56

  LoRusso, Patricia Mucci ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Estrogen receptor; Human epidermal growth factor receptor 2; Mammalian target of rapamycin; mTOR

Indexed keywords

AMINOTRANSFERASE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GAMMA GLUTAMYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIPENDOXIFENE; PLACEBO; PROTEIN KINASE B; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; ZOLEDRONIC ACID;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BONE METASTASIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CELLULITIS; DEPRESSION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INFECTION; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MAXIMUM PLASMA CONCENTRATION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PAIN; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; PROGNOSIS; TOR SERINE-THREONINE KINASES;

EID: 84868237217     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000343063     Document Type: Review

References (59)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277- 300
2. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology TM : Breast Cancer. 2011. http://www nccn.org/professionals/ physician-gls/f- guidelines.asp . Accessed February 23, 2012
3. Germano S, O'Driscoll L: Breast cancer: Understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine. Curr Cancer Drug Targets 2009; 9: 398-418
4. Borders EB, Bivona C, Medina PJ: Mammalian target of rapamycin: Biological function and target for novel anticancer agents. Am J Health Syst Pharmacy 2010; 67: 2095-2106
5. McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM: Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 2010; 10(suppl 3):S59-S65
6. Sheri A, Martin LA, Johnston S: Targeting endocrine resistance: Is there a role for mTOR inhibition? Clin Breast Cancer 2010; 10(suppl 3):S79-S85
7. Yip CK, Murata K, Walz T, Sabatini DM, Kang SA: Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 2010; 38: 768-774
8. Johnston SR: New strategies in estrogen receptor- positive breast cancer. Clin Cancer Res 2010; 16: 1979-1987
9. Margariti N, Fox SB, Bottini A, Generali D: 'Overcoming breast cancer drug resistance with mTOR inhibitors'. Could it be a myth or a real possibility in the short-term future? Breast Cancer Res Treat 2011; 128: 599-606
10. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127 (Pubitemid 39485684)
11. Junttila TT, Akita RW, Parsons K, et al: Ligand- independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15: 429-440
12. Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395-402 (Pubitemid 47539306)
13. Perez-Tenorio G, Stal O: Activation of AKT/ PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002; 86: 540-545 (Pubitemid 34185089)
14. deGraffenried LA, Friedrichs WE, Russell DH, et al: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004; 10: 8059-8067
15. Kim EK, Kim HA, Koh JS, et al: Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res Treat 2011; 126: 93-99
16. Tokunaga E, Kimura Y, Mashino K, et al: Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006; 13: 137-144
17. Sadler TM, Gavriil M, Annable T, Frost P, Greenberger LM, Zhang Y. Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus Endocr Relat Cancer 2006; 13: 863-873 (Pubitemid 44763262)
18. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al: Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006; 66: 5549-5554 (Pubitemid 43927103)
19. Buckner JC, Forouzesh B, Erlichman C, et al: Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest New Drugs 2010; 28: 334-342
20. Carpenter JT, Roche H, Campone M, et al: Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer Presented at the 2005 ASCO Annual Meeting, May 13-15, 2005, Orlando, Fla., USA
21. Chow LWC, Sun Y, Jassem J, et al: Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Presented at the 29th Annual San Antonio Breast Cancer Symposium, December 14-17, 2006, San Antonio, Tex., USA
22. Chan S, Scheulen ME, Johnston S, et al: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23: 5314-5322 (Pubitemid 46206985)
23. Raymond E, Alexandre J, Faivre S, et al: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22: 2336-2347 (Pubitemid 41115390)
24. Atkins MB, Hidalgo M, Stadler WM, et al: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918 (Pubitemid 41103603)
25. Treeck O, Wackwitz B, Haus U, Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 2006; 102: 292-299 (Pubitemid 44041641)
26. Lu CH, Wyszomierski SL, Tseng LM, et al: Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007; 13: 5883-5888 (Pubitemid 47583915)
27. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, deGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007; 18: 1323-1328 (Pubitemid 47305004)
28. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43: 83-95 (Pubitemid 38283132)
29. Kovarik JM, Hartmann S, Figueiredo J, et al: Effect of food on everolimus absorption: Quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 2002; 22: 154- 159 (Pubitemid 34112877)
30. Ellard SL, Clemons M, Gelmon KA, et al: Randomized phase II study comparing two schedules of everolimus in patients with recurrent/ metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27: 4536-4541
31. Maas N, Harbeck N, du Bois A, et al: RADAR: A randomized discontinuation phase II study to determine the efficacy of RAD001 (RAD) in breast cancer (BC) patients (pts) with bone metastases only (GBG41). Presented at the American Society of Clinical Oncology Breast Cancer Symposium, October 8-10, 2009, San Francisco, Calif., USA
32. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor- positive advanced breast cancer. N Engl J Med 2012; 366: 520-529
33. Hortobagyi GN, Piccart M, Rugo H, et al: Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO 2 Phase III trial. Presented at the 34th Annual San Antonio Breast Cancer Symposium, December 6-10, 2011, San Antonio, Tex., USA
34. Piccart M, Noguchi S, Pritchard K I et al: Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. Presented at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago, Ill., USA
35. Bachelot T, Bourgeir C, Cropet C, et al: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO Study. J Clin Oncol 2012; 30: 2718-2724
36. Baselga J, Semiglazov V, van Dam P, et al: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27: 2630-2637
37. Badin F, Romond E, Chambers M, et al: A phase II trial of fulvestrant and RAD001 (everolimus) in patients with metastatic estrogen receptor positive breast cancer after aromatase inhibitor failure; a study in progress. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, Tex., USA
38. Jerusalem G, Fasolo A, Dieras V, et al: Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pretreated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011; 125: 447-455
39. Andre F, Campone M, O'Regan R, et al: Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010; 28: 5110- 5115
40. Dalenc F, Campone M, Hupperets P, et al: Everolimus in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial. Presented at the 2010 ASCO Annual Meeting, June 4-8, 2010, Chicago, Ill., USA
41. Morrow PKH, Wulf GM, Ensor J, et al: Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant HER2-overexpressing breast cancer. J Clin Oncol 2011; 29: 3126-3132
42. Mayer IA, Burris H, Bendel J, et al: A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer. Presented at the 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, Tex., USA
43. Gonzalez-Angulo A, Green MC, Murray JL, et al: Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) vs. the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). Presented at the 2011 ASCO Annual Meeting, June 3-7, 2011, Chicago, Ill., USA
44. Rugo H S, Pritchard K I, Gnant M, et al: Everolimus (EVE) for postmenopausal women with advanced breast cancer (ABC) refractory to letrozole or anastrozole: Longterm efficacy and safety results of the BOLERO- 2 trial. Presented at the 8th European Breast Cancer Conference, March 21-24, 2012, Vienna, Austria
45. Leung E, Kim JE, Rewcastle GW, Finlay GJ, guley BC: Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther 2011; 11: 938- 946
46. Chresta CM, Davies BR, Hickson I, et al: AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010; 70: 288-298
47. Bhagwat SV, Gokhale PC, Crew AP, et al: Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: Distinct from rapamycin. Mol Cancer Ther 2011; 10: 1394-1406
48. Tanaka H, Yoshida M, Tanimura H, et al: The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res 2011; 17: 3272-3281
49. Mallon R, Feldberg LR, Lucas J, et al: Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res 2011; 17: 3193-3203
50. Yaguchi S, Fukui Y, Koshimizu I, et al: Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006; 98: 545-556 (Pubitemid 43898818)
51. Rivera VM, Squillace RM, Miller D, et al: Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther 2011; 10: 1059-1071
52. Hartford CM, Desai AA, Janisch L, et al: A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 2009; 15: 1428- 1434
53. Schnell CR, Stauffer F, Allegrini PR, et al: Effects of the dual phosphatidylinositol 3-kinase/ mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: Implications for clinical imaging. Cancer Res 2008; 68: 6598-6607
54. Brunner-Kubath C, Shabbir W, Saferding V, et al: The PI3 kinase/mTOR blocker NVPBEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat 2011; 129: 387- 400
55. Laird D, on behalf of the Exelixis Research and Development: XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR. Presented at the AACR-NCIEORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, October 22-26, 2007, San Francisco, Calif., USA
56. LoRusso P, Markman B, Tabernero C, et al: A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. Presented at the 2009 ASCO Annual Meeting, May 29- June 3, 2009, Orlando, Fla., USA
57. Sampath D, Fields C, Prior WW, Parsons K, Friedman LS, Lewis-Phillips GD: Combination therapy of the novel PI3K inhibitor GDC-0941 and dual PI3K/mTOR inhibitor GDC-0980 with trastuzumab-DM1 antibody drug conjugate enhances antitumor activity in preclinical breast cancer models in vitro. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, Tex., USA
58. Dolly S, Wagner AJ, Bendell JC, et al: A firstin- human, phase l study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or nonHodgkin's lymphoma. Presented at the 2010 ASCO Annual Meeting, June 4-8, 2010, Chicago, Ill., USA
59. Wagner AJ, Von Hoff DH, LoRusso PM, et al: A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. Presented at the 2009 ASCO Annual Meeting, May 29-June 3, 2009, Orlando, Fla., USA